Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MenACWY-CRM Co-administered with Travel Vaccines
NCT01466387Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2011
- Primary completion
- Apr 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen in meningococcal disease (6 arms), sponsored by Novartis. Primary endpoints: Geometric Mean Anti-typhoid Vi Antibody Concentrations, Geometric Mean Anti-Yellow Fever Antibody Titer and 2 more. Started Nov 2011; status: completed.
02
Drugs
neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT01466387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01466387.